Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Ziprasidone
|
| gptkbp:activities |
dopamine receptor antagonist
serotonin receptor antagonist |
| gptkbp:brand |
gptkb:Geodon
|
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:class |
atypical antipsychotic
|
| gptkbp:clinical_trial |
studies on efficacy
studies on safety acute mania in bipolar disorder long-term management of schizophrenia maintenance therapy in bipolar disorder |
| gptkbp:contraindication |
concurrent use of certain medications
hypersensitivity to ziprasidone |
| gptkbp:dosage_form |
oral capsule
injection solution |
| gptkbp:education |
avoid alcohol
take with food do not stop abruptly report any unusual symptoms |
| gptkbp:effective_date |
gptkb:2001
|
| gptkbp:form |
gptkb:beer
injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Geodon
|
| gptkbp:ingredients |
C21 H24 N4 OS
|
| gptkbp:interacts_with |
with antidepressants
with antihypertensives with other antipsychotics |
| gptkbp:is_atype_of |
N05 A E01
|
| gptkbp:is_monitored_by |
gptkb:weight
blood glucose lipid levels ECG for QT prolongation |
| gptkbp:is_used_for |
treatment of schizophrenia
treatment of bipolar disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
7 hours
|
| gptkbp:manager |
oral
intramuscular |
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
ziprasidone N-oxide ziprasidone sulfoxide |
| gptkbp:previous_name |
gptkb:ziprasidone
|
| gptkbp:research_areas |
side effects management
bipolar disorder treatment schizophrenia treatment |
| gptkbp:rounds |
urine
feces |
| gptkbp:side_effect |
nausea
restlessness drowsiness weight gain extrapyramidal symptoms |
| gptkbp:symptoms |
anxiety
nausea insomnia |
| gptkbp:type_of |
138-79-0
|